<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877706</url>
  </required_header>
  <id_info>
    <org_study_id>12 386 02</org_study_id>
    <nct_id>NCT02877706</nct_id>
  </id_info>
  <brief_title>Autoimmune Cytopenias : Midi-Pyrenees Registry</brief_title>
  <acronym>CARMEN</acronym>
  <official_title>Autoimmune Cytopenias : Midi-Pyrenees Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CARMEN is a clinical registry of all incident adult Immune thrombocytopenia (ITP) and
      Autoimmune Hemolytic anemia (AIHA) patients in the Midi-Pyrenees region (South of France). It
      is aimed at describing ITP and AIHA clinical features, assessing the risk-benefit ratio of
      second-line treatments (SLTs) and adherence to guidelines for ITP and AIHA management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of Immune thrombocytopenia (ITP) and AIHA</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of new cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding symptoms</measure>
    <time_frame>Baseline and each year</time_frame>
    <description>Description of bleeding symptoms : number of bleeding symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>10 years</time_frame>
    <description>Efficacy outcomes response rate, complete response rate. Effectiveness outcomes are overall and cause specific mortality, absence of need of second-line ITP treatment, withdrawal of corticosteroids and quality of life (SF-36 scale).
Safety outcomes are adverse drug reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to ITP management guidelines.</measure>
    <time_frame>10 years</time_frame>
    <description>Percentage of patients who benefitted from the recommended examinations to detect secondary ITP and the percentage of patients who benefitted from the recommended first-line and second line treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding symptoms</measure>
    <time_frame>Each year during 10 years</time_frame>
    <description>Description of bleeding symptoms : number of bleeding symptoms</description>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no specific intervention</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ITP and AIHA case recording in the Midi-Pyrénées region, South of France. ITP
        patients are treated by internal medicine and hematology practitioners actually spread in
        one tertiary hospital (located in Toulouse and including one hematology and six internal
        medicine departments) and 14 peripheral public or private hospitals. All these
        practitioners take actively part to the network of the Midi-Pyrénées Competence Center for
        Autoimmune Cytopenias.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 18 years

          -  newly diagnosed ITP or AIHA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moulis Guillaume, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hopsital Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moulis Guillaume, MD PhD</last_name>
    <email>moulis.g@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adoue Daniel, MD</last_name>
    <email>adoue.d@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moulis Guillaume, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

